Saturday, September 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Analysts Identify Significant Upside Potential in Asure Software Shares

Andreas Sommer by Andreas Sommer
September 6, 2025
in Analysis, Tech & Software, Turnaround
0
Asure Software Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Despite presenting a mixed financial picture, Asure Software is capturing significant analyst optimism for its future trajectory. The cloud-based human capital management specialist is experiencing a notable sentiment shift, driven not by current performance but by substantial growth expectations. Market experts highlight a considerable gap between the stock’s present valuation and their projected price targets.

The recent strategic acquisition of Lathem Time Corporation appears to be a pivotal move. Management used their July quarterly presentation to substantially upgrade their annual guidance, raising it from the previous $134-138 million range to $138-142 million. This confident forecast revision, coming immediately after finalizing the acquisition, overshadowed disappointing Q2 results and propelled the stock upward by 8% in after-hours trading following the announcement.

This optimism is reflected in concrete analyst actions. Multiple firms reaffirmed their buy recommendations on Friday, with several establishing price targets reaching as high as $15. This represents potential appreciation of nearly 70% from current trading levels. Even more conservative estimates remain significantly above $13, suggesting widespread belief that the market is undervaluing Asure’s long-term growth narrative.

Should investors sell immediately? Or is it worth buying Asure Software?

Institutional investors are demonstrating substantial confidence through increased positions. During the last quarter, these major market participants boosted their ownership in Asure by over 36%, now controlling more than 70% of outstanding shares. This strong institutional backing, maintained despite current GAAP losses, indicates deep conviction in the company’s turnaround strategy. Management anticipates achieving GAAP profitability by the fourth quarter of 2025.

The coming weeks present critical opportunities for Asure to validate this optimism. Company leadership is scheduled to participate in two investor conferences in mid-September, providing platforms to elaborate on their strategic vision and reinforce market confidence. For investors who believe in the cloud HCM growth story, Asure represents one of the market’s most compelling opportunities.

Ad

Asure Software Stock: Buy or Sell?! New Asure Software Analysis from September 6 delivers the answer:

The latest Asure Software figures speak for themselves: Urgent action needed for Asure Software investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 6.

Asure Software: Buy or sell? Read more here...

Tags: Asure Software
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Procore Technologies Stock
Analysis

Institutional Investors Target Procore Technologies as Sector Digitizes

September 6, 2025
Aligos Therapeutics Inc Stock
Analysis

Aligos Therapeutics Shares Surge Ahead of Key Scientific Forums

September 6, 2025
Cytosorbents Stock
Analysis

A Watershed Year Approaches for Cytosorbents as FDA Decision Looms

September 6, 2025
Next Post
Big 5 Sporting Goods Stock

Shareholders to Decide Fate of Big 5 Sporting Goods Acquisition

Robinhood Stock

Robinhood's S&P 500 Inclusion: A Watershed Moment for Fintech

Boyd Gaming Stock

Strategic Divestiture Fuels Boyd Gaming's Financial Transformation

Recommended

Fiserv Stock

Fiserv Faces Mounting Pressure as Growth Concerns Spark Legal and Analyst Backlash

3 weeks ago
Biotechnology Stock Exchange

Arvinas Reports LowerthanExpected Quarterly Losses and Positive Financial Outlook

2 years ago
Healthcare-IT-and-tech

Electromed Inc to Release Quarterly Earnings Report

2 years ago
Compass Therapeutics Stock

A Closer Look at Compass Therapeutics’ Clinical and Financial Trajectory

3 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA Broadcom C Coinbase COST CRWD DIS Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSFT NIO Nvidia Opendoor Oracle PayPal Pepsi PLTR Realty Income Red Cat Robinhood Rocket Lab USA SMCI Strategy Tesla TSLA Unitedhealth Viking Therapeutics
No Result
View All Result

Highlights

A New Chapter Begins as Walgreens Boots Alliance Goes Private in Landmark Deal

A Watershed Year Approaches for Cytosorbents as FDA Decision Looms

Micron Stock Soars to Unprecedented Highs on AI-Driven Demand

Blue Ridge Bankshares Navigates a Complex Recovery Path

Mixed Signals for UniFirst Investors

Huntington Bancshares Shares Face Investor Skepticism Despite Solid Performance

Trending

Procore Technologies Stock
Analysis

Institutional Investors Target Procore Technologies as Sector Digitizes

by Felix Baarz
September 6, 2025
0

Major financial institutions are establishing new positions in Procore Technologies, signaling a potential shift in sentiment toward...

Xtant Medical Stock

Xtant Medical’s Strategic Shift: A Bold Move or Misstep?

September 6, 2025
Aligos Therapeutics Inc Stock

Aligos Therapeutics Shares Surge Ahead of Key Scientific Forums

September 6, 2025
Walgreens Stock

A New Chapter Begins as Walgreens Boots Alliance Goes Private in Landmark Deal

September 6, 2025
Cytosorbents Stock

A Watershed Year Approaches for Cytosorbents as FDA Decision Looms

September 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Institutional Investors Target Procore Technologies as Sector Digitizes September 6, 2025
  • Xtant Medical’s Strategic Shift: A Bold Move or Misstep? September 6, 2025
  • Aligos Therapeutics Shares Surge Ahead of Key Scientific Forums September 6, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com